FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386407783> ?p ?o ?g. }

• W4386407783 endingPage "9" @default.
• W4386407783 startingPage "1" @default.
• W4386407783 abstract "Background The association between anti-vascular endothelial growth factor (VEGF) drugs and ocular adverse events (AEs) has been reported, but large real-world studies of their association with systemic AEs are still lacking.Methods A disproportionality analysis of reports from the FDA Adverse Event Reporting System from January 2004 to September 2021 was conducted to detect the significant ADR signals with anti-VEGF drugs (including aflibercept, bevacizumab, brolucizumab, pegaptanib, and ranibizumab).Results A total of 2980 reported cases with 7125 drug-AEs were included. Five drugs were all associated with eye disorders, and pegaptanib and ranibizumab were also associated with cardiac disorders. For ranibizumab, pegaptanib, bevacizumab and aflibercept, the proportions of cardiac AEs were 8.57%, 5.62%, 3.43% and 3.20%, respectively, and the proportions of central nervous AEs were 8.81%, 7.41, 5.86% and 5.68%, respectively. In multiple comparisons, ranibizumab was significantly higher than bevacizumab and aflibercept in the proportion of cardiac AEs (P < 0.001), and ranibizumab was significantly higher than aflibercept in central nervous AEs (P < 0.001).Conclusions Our findings support the associations between anti-VEGF drugs and ocular AEs, cardiac AEs, and central nervous AEs. After intravitreal injection, attention should not only be paid to ocular symptoms, but also to systemic symptoms." @default.
• W4386407783 created "2023-09-05" @default.
• W4386407783 creator A5003426569 @default.
• W4386407783 creator A5010867003 @default.
• W4386407783 creator A5025570071 @default.
• W4386407783 creator A5037146076 @default.
• W4386407783 creator A5043295520 @default.
• W4386407783 creator A5048872057 @default.
• W4386407783 creator A5077442566 @default.
• W4386407783 date "2023-09-04" @default.
• W4386407783 modified "2023-10-01" @default.
• W4386407783 title "A real-world disproportionality analysis of anti-VEGF drugs from the FDA Adverse Event Reporting System" @default.
• W4386407783 cites W1912721404 @default.
• W4386407783 cites W1983763042 @default.
• W4386407783 cites W1988100739 @default.
• W4386407783 cites W1999647970 @default.
• W4386407783 cites W2000541335 @default.
• W4386407783 cites W2002986738 @default.
• W4386407783 cites W2026216391 @default.
• W4386407783 cites W2064716383 @default.
• W4386407783 cites W2074289946 @default.
• W4386407783 cites W2078916806 @default.
• W4386407783 cites W2091995353 @default.
• W4386407783 cites W2113514677 @default.
• W4386407783 cites W2151797091 @default.
• W4386407783 cites W2171962482 @default.
• W4386407783 cites W2289200040 @default.
• W4386407783 cites W2416155145 @default.
• W4386407783 cites W2602444060 @default.
• W4386407783 cites W2743639829 @default.
• W4386407783 cites W2895211690 @default.
• W4386407783 cites W2896939971 @default.
• W4386407783 cites W2921434986 @default.
• W4386407783 cites W2937282237 @default.
• W4386407783 cites W2947995207 @default.
• W4386407783 cites W2995833605 @default.
• W4386407783 cites W3012547569 @default.
• W4386407783 cites W3024237066 @default.
• W4386407783 cites W3029640339 @default.
• W4386407783 cites W3037246402 @default.
• W4386407783 cites W3048155870 @default.
• W4386407783 cites W3118188575 @default.
• W4386407783 cites W3138856262 @default.
• W4386407783 cites W3156078512 @default.
• W4386407783 cites W3197750160 @default.
• W4386407783 cites W4211068092 @default.
• W4386407783 cites W4213072361 @default.
• W4386407783 cites W4220938182 @default.
• W4386407783 cites W4237409402 @default.
• W4386407783 cites W4285386130 @default.
• W4386407783 cites W4294169062 @default.
• W4386407783 cites W4302027988 @default.
• W4386407783 cites W4309271194 @default.
• W4386407783 cites W4320718812 @default.
• W4386407783 cites W4323812692 @default.
• W4386407783 doi "https://doi.org/10.1080/14740338.2023.2250717" @default.
• W4386407783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37665052" @default.
• W4386407783 hasPublicationYear "2023" @default.
• W4386407783 type Work @default.
• W4386407783 citedByCount "0" @default.
• W4386407783 crossrefType "journal-article" @default.
• W4386407783 hasAuthorship W4386407783A5003426569 @default.
• W4386407783 hasAuthorship W4386407783A5010867003 @default.
• W4386407783 hasAuthorship W4386407783A5025570071 @default.
• W4386407783 hasAuthorship W4386407783A5037146076 @default.
• W4386407783 hasAuthorship W4386407783A5043295520 @default.
• W4386407783 hasAuthorship W4386407783A5048872057 @default.
• W4386407783 hasAuthorship W4386407783A5077442566 @default.
• W4386407783 hasConcept C118487528 @default.
• W4386407783 hasConcept C126322002 @default.
• W4386407783 hasConcept C197934379 @default.
• W4386407783 hasConcept C2776694085 @default.
• W4386407783 hasConcept C2777512022 @default.
• W4386407783 hasConcept C2777802072 @default.
• W4386407783 hasConcept C2778749236 @default.
• W4386407783 hasConcept C2781100027 @default.
• W4386407783 hasConcept C71924100 @default.
• W4386407783 hasConcept C98274493 @default.
• W4386407783 hasConceptScore W4386407783C118487528 @default.
• W4386407783 hasConceptScore W4386407783C126322002 @default.
• W4386407783 hasConceptScore W4386407783C197934379 @default.
• W4386407783 hasConceptScore W4386407783C2776694085 @default.
• W4386407783 hasConceptScore W4386407783C2777512022 @default.
• W4386407783 hasConceptScore W4386407783C2777802072 @default.
• W4386407783 hasConceptScore W4386407783C2778749236 @default.
• W4386407783 hasConceptScore W4386407783C2781100027 @default.
• W4386407783 hasConceptScore W4386407783C71924100 @default.
• W4386407783 hasConceptScore W4386407783C98274493 @default.
• W4386407783 hasLocation W43864077831 @default.
• W4386407783 hasLocation W43864077832 @default.
• W4386407783 hasOpenAccess W4386407783 @default.
• W4386407783 hasPrimaryLocation W43864077831 @default.
• W4386407783 hasRelatedWork W1990147459 @default.
• W4386407783 hasRelatedWork W2027593799 @default.
• W4386407783 hasRelatedWork W2050270337 @default.
• W4386407783 hasRelatedWork W2053379002 @default.
• W4386407783 hasRelatedWork W2106393433 @default.
• W4386407783 hasRelatedWork W2115274617 @default.

• next